Maule Francesca, Bresolin Silvia, Rampazzo Elena, Boso Daniele, Della Puppa Alessandro, Esposito Giovanni, Porcù Elena, Mitola Stefania, Lombardi Giuseppe, Accordi Benedetta, Tumino Manuela, Basso Giuseppe, Persano Luca
Department of Woman and Child Health, University of Padova, Padova, IT.
Istituto di Ricerca Pediatrica (IRP) - Città della Speranza, Padova, IT.
Oncotarget. 2016 Aug 23;7(34):54632-54649. doi: 10.18632/oncotarget.10565.
Glioblastoma (GBM) is the most devastating tumor of the brain, characterized by an almost inevitable tendency to recur after intensive treatments and a fatal prognosis. Indeed, despite recent technical improvements in GBM surgery, the complete eradication of cancer cell disseminated outside the tumor mass still remains a crucial issue for glioma patients management. In this context, Annexin 2A (ANXA2) is a phospholipid-binding protein expressed in a variety of cell types, whose expression has been recently associated with cell dissemination and metastasis in many cancer types, thus making ANXA2 an attractive putative regulator of cell invasion also in GBM.Here we show that ANXA2 is over-expressed in GBM and positively correlates with tumor aggressiveness and patient survival. In particular, we associate the expression of ANXA2 to a mesenchymal and metastatic phenotype of GBM tumors. Moreover, we functionally characterized the effects exerted by ANXA2 inhibition in primary GBM cultures, demonstrating its ability to sustain cell migration, matrix invasion, cytoskeletal remodeling and proliferation. Finally, we were able to generate an ANXA2-dependent gene signature with a significant prognostic potential in different cohorts of solid tumor patients, including GBM.In conclusion, we demonstrate that ANXA2 acts at multiple levels in determining the disseminating and aggressive behaviour of GBM cells, thus proving its potential as a possible target and strong prognostic factor in the future management of GBM patients.
胶质母细胞瘤(GBM)是最具毁灭性的脑部肿瘤,其特征是在强化治疗后几乎不可避免地会复发,预后不良。事实上,尽管近年来GBM手术技术有所改进,但彻底清除肿瘤块外播散的癌细胞仍是胶质瘤患者治疗中的关键问题。在此背景下,膜联蛋白2A(ANXA2)是一种在多种细胞类型中表达的磷脂结合蛋白,其表达最近在许多癌症类型中与细胞播散和转移相关,因此ANXA2也成为GBM中一种有吸引力的潜在细胞侵袭调节因子。在此我们表明,ANXA2在GBM中过表达,且与肿瘤侵袭性和患者生存率呈正相关。特别是,我们将ANXA2的表达与GBM肿瘤的间充质和转移表型联系起来。此外,我们在原发性GBM培养物中对ANXA2抑制作用的功能进行了表征,证明其具有维持细胞迁移、基质侵袭、细胞骨架重塑和增殖的能力。最后,我们能够生成一个依赖ANXA2的基因特征,在包括GBM在内的不同实体瘤患者队列中具有显著的预后潜力。总之,我们证明ANXA2在决定GBM细胞的播散和侵袭行为方面在多个层面发挥作用,从而证明其作为GBM患者未来治疗中可能的靶点和强大预后因素的潜力。